Author:
Neves Mario Fritsch,Schiffrin Ernesto L.
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153.
2. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995–1003.
3. Naruse M, Tanabe A, Sato A, et al.: Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002, 40:28–33. A recent original study providing evidence that aldosterone escape may occur during long-term use of ARBs via activation of AT2 receptors, which may attenuate beneficial effects of these drugs on cardiac tissue. The addition of low-dose spironolactone induced further cardioprotection in ARB-treated rats.
4. Li S, Wu P, Zhong S, Guo Z, et al.: Effects of long-term enalapril and losartan therapy of hypertension on cardiovascular aldosterone. Horm Res 2001, 55:293–297.
5. Schmidt BM, Georgens AC, Martin N, et al.: Interaction of rapid nongenomic cardiovascular aldosterone effects with the adrenergic system. J Clin Endocrinol Metab 2001, 86:761–767.
Cited by
50 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献